Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits
By Ernie Mundell HealthDay Reporter
THURSDAY, May 2, 2024 -- Johnson & Johnson announced Wednesday that it would pay out more than $6.5 billion over the next 25 years to settle existing lawsuits claiming that its talc-containing products caused ovarian cancer.
The settlement still awaits approval from claimants.
Claims from consumers that baby powders and other J & J talc-based products cause ovarian cancer have dogged the company for years, leading J & J to discontinue sales of these products.
According to NBC News, J & J attempted to resolve the lawsuits through the bankruptcy of a subsidiary, LTL Management, but courts twice blocked that effort. LTL Management was created to absorb the company’s talc liabilities, and this is the third time bankruptcy has been filed in an effort to resolve the lawsuits.
However, in the prior bankruptcy proceedings, claimants did not have an opportunity to vote. This time, J & J is initiating a three-month voting period for claimants. If 75% of voters approve, it would signal a bankruptcy settlement that would end the litigation entirely and prevent future lawsuits, J&J executives said on a call with investors on Wednesday.
“We firmly believe this plan is in the best interest of claimants and should receive a favorable and immediate confirmation from the bankruptcy court,” said Erik Haas, J&J’s worldwide vice president of litigation, NBC News reported.
A few cases involve claimants who contend that long-term use of talc products caused a form of lung cancer called mesothelioma; those cases are being resolved outside the new settlement plan. According to NBC News, J &J said it has already resolved 95% of the mesothelioma claims.
J & J also announced that it has reached “final and comprehensive” settlements that should end a probe launched by 40 states investigating whether the company misled patients about the safety of its talc baby powder and other talc-based products, NBC News reported.
Sources
- NBC News, May 1, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
AI May Bring a Better Blood Test for Ovarian Cancer
WEDNESDAY, April 10, 2024 -- Using AI to track fragments of tumor-associated DNA in the blood, scientists say they may be close to an accurate test for a silent killer: Ovarian...
EPA Issues Final Rule Banning Asbestos
MONDAY, March 18, 2024 -- The last remnants of asbestos use in the United States have now been banned by the Environmental Protection Agency. While the known carcinogen has...
New Treatment Brings Hope for Rare, Deadly Cancer Linked to Asbestos, Malignant Mesothelioma
THURSDAY, Feb. 15, 2024 -- Mick worked in a factory boiler room in the 1970s, where he was exposed to asbestos. He didn’t think much of it until 2018, when he began to feel...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.